The minimum number of target lesions that need to be measured to be representative of the total number of target lesions (according to RECIST)

British Journal of Radiology

Volumn 82, Issue 980, 2009, Pages 681-686

  Darkeh, M H S E ^a   Suzuki, C ^a,b,c   Torkzad, Michael R ^d,e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIGESTIVE SYSTEM CANCER; FEMALE; HEAD AND NECK CANCER; HUMAN; IMAGING SYSTEM; KIDNEY CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MELANOMA; METASTASIS; OUTCOME ASSESSMENT; OVARY CANCER; PROSTATE CANCER; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SOLID TUMOR; TARGET ORGAN; TREATMENT OUTCOME; TUMOR REGRESSION;

CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 67650650691     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/72829563     Document Type: Article

References (18)

1. Michaelis LC, Ratain MJ. Measuring response in a post- RECIST world: from black and white to shades of grey. Nat Rev Cancer 2006;6:409-414
2. Husband JE, Schwartz LH, Spencer J, Ollivier L, King DM, Johnson R, et al; International Cancer Imaging Society. Evaluation of the response to treatment of solid tumours - a consensus statement of the International Cancer Imaging Society. Br J Cancer 2004;90:2256-2260
3. Suzuki C, Jacobsson H, Hatschek T, Torkzad MR, Bodén K, Eriksson-Alm Y, et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics 2008;28:329-344
4. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006;42:1031-1039
5. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216
6. Marten K, Auer F, Schmidt S, Rummeny EJ, Engelke C. Automated CT volumetry of pulmonary metastases: the effect of a reduced growth threshold and target lesion number on the reliability of therapy response assessment using RECIST criteria. Eur Radiol 2007;17:2561-2571
7. Zacharia TT, Saini S, Halpern EF, Sumner JE. CT of colon cancer metastases to the liver using modified RECIST criteria: determining the ideal number of target lesions to measure. AJR Am J Roentgenol 2006;186:1067-1070 (Pubitemid 46100209)
8. Schwartz LH, Mazumdar M, Brown W, Smith A, Panicek DM. Variability in response assessment in solid tumors: effect of number of lesions chosen for measurement. Clin Cancer Res 2003;9:4318-4323 (Pubitemid 37248386)
9. Assouline S, Meyer RM, Infante-Rivard C, Connors JM, Belch A, Crump M, et al. Development of adapted RECIST criteria to assess response in lymphoma and their comparison to the International Workshop Criteria. Leuk Lymphoma 2007;48:513-520 (Pubitemid 46487758)
10. Shah GD, Kesari S, Xu R, Batchelor TT, O'Neill AM, Hochberg FH, et al. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro Oncol 2006;8:38-46. (Pubitemid 43154449)
11. Barnacle AM, McHugh K. Limitations with the response evaluation criteria in solid tumors (RECIST) guidance in disseminated pediatric malignancy. Pediatr Blood Cancer 2006;46:127-134 (Pubitemid 43076061)
12. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004;15:257-260 (Pubitemid 38262625)
13. Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G. Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res 2005;11:5223-5232 (Pubitemid 41003710)
14. Tuma RS. Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints. J Natl Cancer Inst 2006;98:1272-1274
15. Eisenhauer EA. Response evaluation: beyond RECIST. Ann Oncol 2007;18(Suppl 9):ix29-32.
16. Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 2006;24:3245-3251 (Pubitemid 46622065)
17. Fraioli F, Bertoletti L, Napoli A, Calabrese FA, Masciangelo R, Cortesi E, et al. Volumetric evaluation of therapy response in patients with lung metastases. Preliminary results with a computer system (CAD) and comparison with unidimensional measurements. Radiol Med (Torino) 2006;111:365-375
18. Marten K, Auer F, Schmidt S, Kohl G, Rummeny EJ, Engelke C. Inadequacy of manual measurements compared to automated CT volumetry in assessment of treatment response of pulmonary metastases using RECIST criteria. Eur Radiol 2006;16:781-790 (Pubitemid 43380236)